When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
MGTA - Magenta bails on cell therapy in inherited metabolic disorders
Magenta Therapeutics Inc.
Making a "strategic decision," Magenta Therapeutics (NASDAQ:MGTA) will discontinue enrollment in a Phase 2 clinical trial evaluating MGTA-456 in patients with inherited metabolic disorders, deciding instead to focus its resources on stem cell mobilization and conditioning programs.
More news on: Magenta Therapeutics, Inc., Healthcare stocks news,